These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

108 related articles for article (PubMed ID: 38570141)

  • 1. Towards more tolerable subcutaneous administration: Review of contributing factors for improving combination product design.
    Mathias N; Huille S; Picci M; Mahoney RP; Pettis RJ; Case B; Helk B; Kang D; Shah R; Ma J; Bhattacharya D; Krishnamachari Y; Doucet D; Maksimovikj N; Babaee S; Garidel P; Esfandiary R; Gandhi R
    Adv Drug Deliv Rev; 2024 Jun; 209():115301. PubMed ID: 38570141
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmaceutical and biotech industry perspectives on optimizing patient experience and treatment adherence through subcutaneous drug delivery design.
    Stevenson J; Poker R; Schoss J; Campbell M; Everitt C; Holly B; Stones N; Pettis RJ; Sanchez-Felix M
    Adv Drug Deliv Rev; 2024 Jun; 209():115322. PubMed ID: 38677443
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Subcutaneous Delivery of High-Dose/Volume Biologics: Current Status and Prospect for Future Advancements.
    Badkar AV; Gandhi RB; Davis SP; LaBarre MJ
    Drug Des Devel Ther; 2021; 15():159-170. PubMed ID: 33469268
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Accelerating the development of novel technologies and tools for the subcutaneous delivery of biotherapeutics.
    Collins DS; Sánchez-Félix M; Badkar AV; Mrsny R
    J Control Release; 2020 May; 321():475-482. PubMed ID: 32105759
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Subcutaneous Injection Volume of Biopharmaceuticals-Pushing the Boundaries.
    Mathaes R; Koulov A; Joerg S; Mahler HC
    J Pharm Sci; 2016 Aug; 105(8):2255-9. PubMed ID: 27378678
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical Investigation of Large Volume Subcutaneous Delivery up to 25 mL for Lean and Non-Lean Subjects.
    Dang X; Shih H; Sharma R; Angwin-Kaerner DT; Lin K; Kapur S; Thyagarajapuram NR; Shi GH; Collins DS
    Pharm Res; 2024 Apr; 41(4):751-763. PubMed ID: 38443633
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Advances in Large Volume Subcutaneous Injections: A Pilot Tolerability Study of an Innovative Needle-Free Injection Platform.
    Kelley EL; Fernandes A; Pelletier M; Takami EA; Emery C; Dyer B; Jacoski MV; Lozko V; Burgess B; Smith RH
    PDA J Pharm Sci Technol; 2022; 76(6):474-484. PubMed ID: 35296562
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Advanced Formulations/Drug Delivery Systems for Subcutaneous Delivery of Protein-Based Biotherapeutics.
    Lou H; Feng M; Hageman MJ
    J Pharm Sci; 2022 Nov; 111(11):2968-2982. PubMed ID: 36058255
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Safety of recombinant human hyaluronidase PH20 for subcutaneous drug delivery.
    Knowles SP; Printz MA; Kang DW; LaBarre MJ; Tannenbaum RP
    Expert Opin Drug Deliv; 2021 Nov; 18(11):1673-1685. PubMed ID: 34585991
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Tolerability of High-Volume Subcutaneous Injections of a Viscous Placebo Buffer: A Randomized, Crossover Study in Healthy Subjects.
    Dias C; Abosaleem B; Crispino C; Gao B; Shaywitz A
    AAPS PharmSciTech; 2015 Oct; 16(5):1101-7. PubMed ID: 25693652
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A Phase I Study to Assess the Effect of Speed of Injection on Pain, Tolerability, and Pharmacokinetics After High-volume Subcutaneous Administration of Gantenerumab in Healthy Volunteers.
    Portron A; Jordan P; Draper K; Muenzer C; Dickerson D; van Iersel T; Hofmann C
    Clin Ther; 2020 Jan; 42(1):108-120.e1. PubMed ID: 31883703
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparative injection-site pain and tolerability of subcutaneous serum-free formulation of interferonβ-1a versus subcutaneous interferonβ-1b: results of the randomized, multicenter, Phase IIIb REFORMS study.
    Singer B; Bandari D; Cascione M; LaGanke C; Huddlestone J; Bennett R; Dangond F;
    BMC Neurol; 2012 Dec; 12():154. PubMed ID: 23216674
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Improving the outcomes of biopharmaceutical delivery via the subcutaneous route by understanding the chemical, physical and physiological properties of the subcutaneous injection site.
    Kinnunen HM; Mrsny RJ
    J Control Release; 2014 May; 182():22-32. PubMed ID: 24631859
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Patient adherence to and tolerability of self-administered interferon β-1a using an electronic autoinjection device: a multicentre, open-label, phase IV study.
    Lugaresi A; Florio C; Brescia-Morra V; Cottone S; Bellantonio P; Clerico M; Centonze D; Uccelli A; di Ioia M; De Luca G; Marcellusi A; Paolillo A;
    BMC Neurol; 2012 Mar; 12():7. PubMed ID: 22390218
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Drug delivery options to increase patient adherence and satisfaction in the management of rheumatoid arthritis -- focus on subcutaneous tocilizumab.
    Nakashima Y; Kondo M; Miyahara H; Iwamoto Y
    Drug Des Devel Ther; 2014; 8():913-9. PubMed ID: 25045250
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Autoinjectors for large-volume subcutaneous drug delivery: a review of current research and future directions.
    Schneider A; Jost R; Jordi C; Lange J
    Expert Opin Drug Deliv; 2023 Jun; 20(6):815-830. PubMed ID: 37272119
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Relevance of Adalimumab Product Attributes to Patient Experience in the Biosimilar Era: A Narrative Review.
    Allegretti JR; Brady JH; Wicker A; Latymer M; Wells A
    Adv Ther; 2024 May; 41(5):1775-1794. PubMed ID: 38466559
    [TBL] [Abstract][Full Text] [Related]  

  • 18. New ways of insulin delivery.
    Heinemann L
    Int J Clin Pract Suppl; 2010 Feb; (166):29-40. PubMed ID: 20377662
    [TBL] [Abstract][Full Text] [Related]  

  • 19. White Paper on the Value of Time Savings for Patients and Healthcare Providers of Breast Cancer Therapy: The Fixed-Dose Combination of Pertuzumab and Trastuzumab for Subcutaneous Injection as an Example.
    Jackisch C; Manevy F; Frank S; Roberts N; Shafrin J
    Adv Ther; 2022 Feb; 39(2):833-844. PubMed ID: 34988876
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Summative Usability Evaluation of the SCTE-AI Device: A Novel Prefilled Autoinjector for Subcutaneous Testosterone Administration.
    Arora S; Moclair B; Murphy K; Jaffe JS; Kaminetsky JC
    J Sex Med; 2018 Dec; 15(12):1707-1715. PubMed ID: 30393104
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.